501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro.
Liu H, Wei P, Zhang Q, Chen Z, Aviszus K, Downing W, Peterson S, Reynoso L, Downey GP, Frankel SK, Kappler J, Marrack P, Zhang G.
Liu H, et al. Among authors: kappler j.
MAbs. 2021 Jan-Dec;13(1):1919285. doi: 10.1080/19420862.2021.1919285.
MAbs. 2021.
PMID: 34074219
Free PMC article.